timothy sykes logo
NBIX Stock Draws Bullish Targets After Soleno Deal Thumbnail
G Google News

NBIX Stock Draws Bullish Targets After Soleno Deal

TIM SYKES•UPDATED JUN. 3, 2026, 2:33 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Neurocrine Biosciences Inc. stocks have been trading up by 6.24 percent following highly positive drug pipeline and FDA news.

Candlestick Chart

Live Update At 14:32:47 EDT: On Wednesday, June 03, 2026 Neurocrine Biosciences Inc. stock [NASDAQ: NBIX] is trending up by 6.24%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NBIX is trading like a steady grinder, not a meme rocket. Over the last couple of weeks, Neurocrine Biosciences has walked higher from the low $150s to close around $164.59 on 2026/06/03, with a series of higher lows showing dip support. The daily chart for NBIX from 2026/05/11 onward shows a base forming in the $150–$158 area, then a breakout push toward the mid‑$160s after bullish analyst coverage.

Intraday, NBIX has been tight and controlled. On the latest session, five‑minute candles between 09:30 and 14:30 show the stock holding above $160 for most of the day and grinding up toward the high of $164.97. That kind of orderly, low‑drama tape often reflects steady institutional interest rather than pure day‑trader chaos.

Under the hood, Neurocrine Biosciences is printing real numbers. Q1 2026 revenue was about $814.5M, with gross margin near 98.2% and EBIT margin around 29.8%. Net income from continuing operations came in at $197.9M, or about $1.91 diluted EPS. NBIX runs a lean balance sheet with a current ratio of 2.9 and total debt to equity of only 0.12, giving the company room to fund growth without heavy leverage. For traders, that combination of earnings power and balance sheet strength supports the recent bullish analyst calls.

Why Traders Are Watching NBIX Momentum

NBIX is suddenly back on a lot of watchlists, and the catalyst is clear. Goldman Sachs just reinstated coverage of Neurocrine Biosciences with a Buy rating and a $213 price target, highlighting the completed Soleno Therapeutics acquisition. That deal pulls in Vykat XR as a third commercial product for Prader‑Willi syndrome, giving Neurocrine Biosciences another revenue pillar alongside its existing flagship drugs. For traders, more approved products often mean more predictable cash flow and a richer catalyst calendar.

RBC Capital is singing a similar tune. The firm raised its NBIX price target to $183 from $180 and reiterated an Outperform rating after what it called a strong Q1 rebound. The big detail for traders is the physician survey work: endocrinologists see Crenessity usage in congenital adrenal hyperplasia jumping from 23% of patients today to 37% by the end of 2026 and above 50% in five years. That’s a classic multi‑year ramp story, and Neurocrine Biosciences is right in the middle of it.

Bernstein’s initiation adds another layer. The firm launched coverage of NBIX with an Outperform rating and a $221 price target, pointing to two already‑approved key drugs with long exclusivity runways. On top of that, Bernstein called out upside if Crenessity locks down strong market share and osavampator hits in Phase 3. When multiple major shops line up with Buy and Outperform ratings like this, it often pulls more eyeballs into the trade.

Consensus data from FactSet backs that up. NBIX sits at an overall Buy rating with a mean price target around $192, implying meaningful upside from current levels if the Street’s models play out. For active traders, that consensus acts as a psychological magnet: every pullback gets compared to those targets, and every new headline from Neurocrine Biosciences is judged against this bullish backdrop.

More Breaking News

Conclusion

NBIX is not your typical low‑float, low‑fundamentals momentum ticker. Neurocrine Biosciences is throwing off serious cash and backing it with high-margin products, a clean balance sheet, and now an expanded commercial lineup thanks to the Soleno Therapeutics deal and Vykat XR. Q1 2026 generated $197.9M in net income, with operating cash flow of $145.8M and free cash flow of about $136.7M, even while the company spent heavily on investments and business purchases. That kind of cash engine gives management options — and traders love companies that can fund their own growth.

The near‑term story centers on Crenessity’s adoption curves and the Phase 3 path for osavampator, while the medium‑term story leans on Soleno integration and Vykat XR driving additional revenue for NBIX. Upcoming appearances at the William Blair Growth Stock Conference and the Goldman Sachs Global Healthcare Conference in June keep Neurocrine Biosciences in front of Wall Street and can easily spark new headlines or guidance tweaks that day traders will want on their radar.

For now, the tape, the fundamentals, and the Street all lean the same way: constructive. As Tim Sykes likes to remind traders, “The market rewards preparation, not prediction.” That preparation also means sticking to a disciplined plan and avoiding emotional decision‑making in fast‑moving tickers like NBIX. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. With NBIX, that means knowing the key price levels, understanding why Goldman Sachs, Bernstein, and RBC are this positive, and staying ready to react when the next news hit either confirms or challenges the current bullish script. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading NBIX

Millionaire's
POV on NBIX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”